LEQEMBI® IQLIK™ Subcutaneous Autoinjector Named One of TIME’s “Best Inventions of 2025” Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) today announced that LEQEMBI® IQLIK™, a subcutaneous autoinjector…
Regeneron Presents Latest DB-OTO Data Showing Dramatic and Sustained Hearing and Speech Improvements in Children with Profound Genetic Hearing Loss Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for its investigational gene therapy DB-OTO for profound genetic hearing loss…
CVS Health® 2025 Rx Report Highlights the Evolution of Community Pharmacy to Meet Patient Needs CVS Health® (NYSE: CVS) today unveiled its 2025 Rx Report, Community Pharmacy Reimagined, offering a detailed exploration of how community pharmacies are evolving to meet…
AstraZeneca Showcases Transformative Oncology Pipeline with Breakthrough Data Across Multiple Cancer Types at ESMO 2025 AstraZeneca has reaffirmed its leadership in oncology innovation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, set to take place from October…
FDA Approves Updated Indication for AbbVie’s RINVOQ® (upadacitinib) Expanding Access for Patients with Inflammatory Bowel Disease AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) updating the indication…
Innate Pharma to Host Analyst and Investor Event Highlighting Lacutamab Clinical Data and Market Potential on October 28, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biopharmaceutical company focused on innovative immuno-oncology therapies, announced today that it…
BeOne Medicines Earns FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma, Strengthening Its Global Oncology Leadership BeOne Medicines Ltd., a leading global oncology-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has…
Zoetis Receives Positive CVMP Opinion for Lenivia®, a Novel Therapy to Reduce Osteoarthritis Pain in Dogs Zoetis Inc., a global leader in animal health, today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA)…
Bristol Myers Squibb Expands and Diversifies RNA and Cell Therapy Portfolio Through Acquisition of Orbital Therapeutics Bristol Myers Squibb (NYSE: BMY) announced a significant strategic move to strengthen its leadership in the field of cell and gene therapy with the…
Genethon Presents 2-Year Efficacy Results of Low-Dose Micro-Dystrophin Gene Therapy (GNT0004) in Duchenne Muscular Dystrophy at ESGCT 2025 Genethon, a global leader in the research and development of gene therapies for rare genetic disorders, has reported encouraging long-term results from…
Thermo Fisher Scientific Launches Molecular Microscope Diagnostic System to Transform Lung Transplant Rejection Detection and Management Thermo Fisher Scientific Inc., the global leader in serving science, has unveiled an innovative laboratory-developed test (LDT) that aims to revolutionize the detection and…
Charles River and Toxys Partner to Advance NAM-Based Developmental Toxicity Testing Through ReproTracker® Collaboration Charles River Laboratories International, Inc. (NYSE: CRL) and Dutch biotechnology company Toxys have announced a strategic collaboration that aims to reshape the landscape of developmental and…